1. McDermott MF, Akesentijevich I. The autoinflammatory
syndromes.
Curr Opin Allergy Clin Immunol. 2002;2:511-516.
[PubMed: 14752334]
2. Hull KM, Shoham N, Chae JJ, Aksentijevich I, Kastner DL.
The expanding spectrum of systemic autoinflammatory disorders and
their rheumatic manifestations.
Curr Opin Rheumatol. 2003;15:61-69.
[PubMed: 12496512]
3. Church LD, Churchman SM, Hawkins P, McDermott M. Hereditary
auto-inflammatory disorders and biologics.
Springer Semin
Immunol. 2006;27:494-508.
[PubMed: 16738958]
5. Dinarello CA. Mutations in cryopyrin: bypassing roadblocks
in the caspase-1 inflammasome for IL-1 secretion and disease activity.
Arthritis Rheum.
2007;56:2817-2822.
[PubMed: 17763412]
6. Drenth JP, van der Meer JW. Hereditary periodic fever.
N
Engl J Med. 2001;345:1748-1757.
[PubMed: 11742050]
7. Padeh S. Periodic fever syndromes.
Pediatr Clin North
Am. 2005;52:577-609.
[PubMed: 15820380]
8. Brydges S, Athreya B, Kastner DL. Periodic fever syndromes
in children. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CE, eds. Textbook
of Pediatric Rheumatology. 5th ed. Philadelphia, PA: Elsevier-Saunders;
2005:657-670.
9. Siegal S. Benign paroxysmal peritonitis. Ann Intern
Med. 1945;22:1-21.
10. Samuels J, Aksenitjevich I, Yelizaveta T, et al. Familial
Mediterranean fever at the millennium: clinical spectrum, ancient
mutations, and a survey of 100 American referrals to the National
Institutes of Health.
Medicine (Baltimore). 1998;77:268-297.
[PubMed: 9715731]
11. Aksentijevich I, Torosyan Y, Samuels J, et al. Mutation
and haplotype studies of familial Mediterranean fever reveal new
ancestral relationship and evidence for a high carrier frequency
with reduced penetrance in the Ashkenazi Jewish population.
Am
J Hum Genet. 1999;64:949-962.
[PubMed: 10090880]
12. Ozen S, Karaaslan Y, Ozdemir O, et al. Prevalence of juvenile
chronic arthritis and familial Mediterranean fever in Turkey: a
field study
. J Rheumatol. 1998;25:2445-2449.
[PubMed: 9858443]
13. Kogan A, Shinar Y, Lidar M, et al. Common MEFV mutations
among Jewish ethnic groups in Israel: high frequency of carrier
and phenotype III states and absence of a perceptible biological
advantage for the carrier state.
Am J Med Genet.
2001;102:272-276.
[PubMed: 11484206]
14. Torosyan Y, Aksentijevich I, Sarksian T, et al. A population-based
survey reveals an extremely high FMF carrier frequency in Armenia,
suggesting heterozygote advantage. [abstract] Am
J Hum Genet. 1999;65 (suppl):2266.
15. Pras E, Aksentijevich I, Gruberg L, et al. Mapping of a
gene causing familial Mediterranean fever to the short arm of chromosome
16. N Engl J Med. 1992 291:932-944.
16. The International FMF Consortium. Ancient missense mutations
in a new member of the RoRet gene family are likely to cause familial Mediterranean
fever. Cell 1997;90:797-807.
17. The French FMF Consortium. A candidate gene for familial
Mediterranean fever. Nat Genet. 1997;17:25-31.
18. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M,
Livneh A. The contribution of genotypes at the MEFV and SAA1 loci
to amyloidosis and disease severity in patients with familial Mediterranean
fever.
Arthritis Rheum. 2003;48: 1149-1155.
[PubMed: 12687559]
19. Grateau G, Pecheux C, Cazeneuve C, et al. Clinical versus
genetic diagnosis of familial Mediterranean fever.
Q J Med.
2000;93:223-229.
[PubMed: 10787450]
20. Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic
value of genetic testing in 216 Israeli children with familial Mediterranean
fever.
J Rheumatol. 2003;30:185-190.
[PubMed: 12508410]
21. Tchernitchko D, Moutereau S, Legrendre M, et al. MEFV analysis
is of particularly weak diagnostic value for recurrent fevers in
Western European Caucasian patients.
Arthritis Rheum. 2005;52:3603-3605.
[PubMed: 16255051]
22. Booth DR, Gillmore JD, Lachmann HJ, et al. The genetic basis
of autosomal dominant familial Mediterranean fever.
QJM.
2000;93:217-221.
[PubMed: 10787449]
23. Touitou I, Picot MC, Domingo C, et al. The MICA region determines
the first modifier locus in familial Mediterranean fever.
Arthritis Rheum.
2001;44:163-169.
[PubMed: 11212154]
24. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of
pyrin, the familial Mediterranean fever protein, interacts directly
with caspase-1 to modulate IL-1beta production.
Proc Natl Acad
Sci U S A. 2006;103:9982-9987.
[PubMed: 16785446]
25. Papin S, Cuenin S, Agostini L, et al. The SPRY domain of
Pyrin, mutated in familial Mediterranean fever patients, interacts
with inflammasome components and inhibits proIL-1beta processing.
Cell
Death Differ. 2007;14:1457-1466.
[PubMed: 17431422]
26. Chea JJ, Komarov HD, Cheng J, et al. Targeted disruption
of pyrin, the FMF protein, causes heightened sensitivity to endotoxin
and a defect in macrophage apoptosis. Mol Cell.
2003;11: 591-604.
27. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean
fever. A survey of 470 cases and review of the literature.
Am
J Med. 1967;43:227-253.
[PubMed: 5340644]
28. Gedalia A, Adar A, Gorodischer R. Familial Mediterranean
fever in children. J Rheumatol. 1992;19(suppl 35):1-9.
29. Tunca M, Akar S, Onen F, et al for the Turkish FMF Study
Group. Familial Mediterranean fever (FMF) in Turkey: results of
a nationwide multicenter study
. Medicine (Baltimore). 2005; 84:1-11.
[PubMed: 15643295]
30. Kaplan E, Mukamel M, Barash J, et al. Protracted febrile
myalgia in children and young adults with familial Mediterranean
fever: analysis of 15 patients and suggested criteria for working
diagnosis. Clin Exp Rheumatol. 2007; 25(Suppl 45):S114-S117.
31. Goldfinger SE. Colchicine for familial Mediterranean fever.
N
Engl J Med. 1972;287:1302.
[PubMed: 4636899]
32. Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country
as the primary risk factor for renal amyloidosis in familial Mediterranean
fever.
Arthritis Rheum. 2007;56:1706-1712.
[PubMed: 17469185]
33. Woo P. Amyloidosis in children.
Baillieres Clin Rheumatol.
1994;8:691-697.
[PubMed: 7954869]
34. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic
amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
N
Engl J Med. 1990;323:508-513.
[PubMed: 2377176]
35. Dember LM, Hawkins PN, Hazenberg BP, et al. Eprodisate for
the treatment of renal disease in AA amyloidosis. N Engl
J Med. 2007;356:2413-2415.
36. Livneh A, Langevitz P, Zemer D, et al. Criteria for the
diagnosis of familial Mediterranean fever.
Arthritis Rheum.
1997;40:1879-1885.
[PubMed: 9336425]
37. Berkun Y, Padeh S, Reichman B, et al. A Single Testing of
Serum Amyloid A Levels as a Tool for Diagnosis and Treatment Dilemmas
in Familial Mediterranean Fever.
Semin Arthritis Rheum.
2007;37:182-188.
[PubMed: 17512038]
38. Zemer D, Revach M, Pras M, et al. A controlled trial of
colchicine in preventing attacks of familial Mediterranean fever.
N
Engl J Med. 1974; 291:932-934.
[PubMed: 4606109]
39. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW.
Colchicine therapy for familial Mediterranean fever. A double- blind
study.
N Engl J Med. 1974;291:934-937.
[PubMed: 4606353]
40. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy
in familial Mediterranean fever. A controlled double-blind study.
Ann Intern
Med. 1974;81:792-794.
[PubMed: 4611296]
41. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine
in the prevention and treatment of the amyloidosis of familial Mediterranean
fever
. N Engl J Med. 1986;314:1001-1005.
[PubMed: 3515182]
42. Kallinich T, Haffner D, Nichues T, et al. Colchicine use
in children and adolescents with familial Mediterranean fever: literature
review and consensus statement. Pediatrics. 2007;119:e474-e483.
43. Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug
transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine
response in familial Mediterranean fever.
J Rheumatol.
2007;34:1540-1544.
[PubMed: 17610314]
44. van der Meer JW, Vossen JM, Radl J, et al. Hyperimmunoglobulinaemia
D and periodic fever: a new syndrome. Lancet. 1984;1:1087-1090.
45. Drenth JP, Haagsma CJ, van der Meer JW, and the International
Hyper-IgD Study Group. Hyperimmunoglobulin D and periodic fever syndrome:
the clinical spectrum in a series of 50 patients.
Medicine
(Baltimore). 1994;73:133-143.
[PubMed: 8190036]
46. Houton SM, Kuis W, Duran M, et al. Mutations in MVK, encoding
mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever
syndrome. Nat Genet. 1999;22:175-177.
47. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the
gene encoding mevalonate kinase cause hyper-IgD and periodic fever
syndrome.
Nat Genet. 1999;22:178-181.
[PubMed: 10369262]
48. Simon A, Mariman EC, van der Meer JW, Drenth JP. A founder
effect in the hyperimmunoglobulinemia D and periodic fever syndrome.
Am
J Med. 2003;114:148-152.
[PubMed: 12586237]
49. Houten SM, Frenkel J, Rijkers GT, Wanders RJ, Kuis W, Waterham
HR. Temperature dependence of mutant mevalonate kinase activity
as pathogenic factor in Hyper-IgD and periodic fever syndrome.
Hum
Mol Genet. 2002;11:3115-3124.
[PubMed: 12444096]
50. Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid
products raises ex vivo interleukin-1 beta secretion in hyperimmunoglobulinemia
D and periodic fever syndrome.
Arthritis Rheum.
2002;46:2794-2803.
[PubMed: 12384940]
51. van der Hilst JC, Drength JP, Bodar EJ, Bijzet J, van der
Meer JW, Simon A. International HIDS Study Group. Serum amyloid
A serum concentrations and genotype do not explain low incidence
of amyloidosis in Hyper-IgD syndrome. Amyloid.
2005;12:115-119.
52. Simon A, Bijzet J, Voorbij HA, Mantovani A, van der Meer
JW, Drenth JP. Effect of inflammatory attacks in the classical type
hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters
of the acute phase response. J Intern Med. 2004;356:247-253.
53. Simon A, Cuisset L, Vincent MF, et al. Molecular analysis
of the mevalonate kinase gene in a cohort of patients with the Hyper-IgD
and Periodic Fever Syndrome: its application as a diagnostic tool.
Ann
Intern Med. 2001;135:338-343.
[PubMed: 11529697]
54. Simon A, Drewe E, Jos WM, et al.
Simvastatin treatment for
inflammatory attacks of the hyperimmunoglobulinemia D and periodic
fever syndrome.
Clin Pharmacol Ther. 2004;75:476-483.
[PubMed: 15116060]
55. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley
RI, Kastner DL. Favorable preliminary experience with etanercept
in two patients with the hyperimmunoglobulinemia D and periodic
fever syndrome.
Arthritis Rheum. 2003;48:2645-2651.
[PubMed: 13130485]
56. Boder EJ, van der Hilst JC, Drenth JP, van der Meer JW,
Simon A. Effect of etanercept and anakinra on inflammatory attacks
in the hyper-IgD syndrome: introducing a vaccination provocation
model. Neth J Med. 2005;63:260-264.
57. Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH,
Toghill PJ. Familial Hibernian fever.
Q J Med.
1982;51:469-480.
[PubMed: 7156325]
58. McDermott MF, Aksentijevich I, Galon J, et al. Germline
mutation in the extracellular domains of the 55 kDa TNF receptor,
TNFR1, define a family of dominantly inherited autoinflammatory
syndromes.
Cell. 1999;97:133-144.
[PubMed: 10199409]
59. Arkwright PD, McDermott MF, Houton SM, et al. Hyper IgD
syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A
shedding and partial response to TNF receptor blockade with etanercept.
Clin Exp
Immunol. 2002;130:484-488.
[PubMed: 12452839]
60. Hull KM, Drewe E, Aksentijevich I, et al. The TNF Receptor-Associated
Periodic Syndrome (TRAPS): emerging concepts of an autoinflammatory
disease.
Medicine (Baltimore). 2002;81: 349-368.
[PubMed: 12352631]
61. Dode C, Andre M, Bienvenu T, et al. The enlarging clinical,
genetic, and population spectrum of tumor necrosis factor receptor-associated
periodic syndrome.
Arthritis Rheum. 2002;46: 2181-2188.
[PubMed: 12209523]
62. Aganna E, Hammond L, Hawkins P, et al. Heterogeneity among
patients with tumor necrosis factor-associated periodic syndrome
phenotypes.
Arthritis Rheum. 2003;48:2632-2644.
[PubMed: 13130484]
63. Drewe E, Powell PT, Issacs JD, et al. Prospective study
of antitumor necrosis factor superfamily 1a and 1b fusion proteins
in tumor necrosis factor associated periodic syndrome (TRAPS): clinical
and laboratory findings in a series of 6 patients.
Rheumatology
(Oxford). 2003;42:235-239.
[PubMed: 12595616]
64. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley
RI, Kastner DL. Favorable preliminary experience with etanercept
in two patients with the hyperimmunoglobulinemia D and periodic
fever syndrome.
Arthritis Rheum. 2003; 48:2645-2651.
[PubMed: 13130485]
65. Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response
to interleukin 1 receptor antagonist in traps.
Am J Med.
2004;117:208-210.
[PubMed: 15300976]
66. Hoffman H, Mueller J, Brodie D, et al. Mutation of a new
gene encoding a putative pyrinlike protein causes familial cold
autoinflammatory syndrome and Muckle-Wells syndrome.
Nat Genet.
2001;29:301-305.
[PubMed: 11687797]
67. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile
neurological cutaneous and articular syndrome is caused by mutations
in CIAS1, a gene highly expressed in polymorphonuclear cells and
chondrocytes.
Am J Hum Genet. 2002;71:198-203.
[PubMed: 12032915]
68. Aksentijevich I, Putnam CD, Remmers EF, et al. The clinical
continuum of cryopyrinopathies: novel CIAS1 mutations in North American
patients and a new cryopyrin model.
Arthritis Rheum.
2007;56:1273-1285.
[PubMed: 17393462]
69. Gattorno M, Tassi S, Carta S, et al. Pattern of IL-1 secretion
on response to lipopolysaccharide and ATP before and after IL-1
blockade in patients with CIAS1 mutations.
Arthritis Rheum. 2007;
56:3138-3148.
[PubMed: 17763411]
70. Neven B, Prieur AM, Petty RE. Cryopyrin-associated periodic
syndromes. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CE, eds. Textbook
of Pediatric Rheumatology. 5th ed. Philadelphia, PA: Elsevier-Saunders;
2005:671-675.
71. Kile RM, Rusk HA. A case of cold urticaria with an unusual
family history. JAMA. 1940;114: 1067-1068.
72. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of
cold-associated acute inflammation in familial cold autoinflammatory
syndrome by interleukin-1 receptor antagonist.
Lancet.
2004;364:1779-1785.
[PubMed: 15541451]
73. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety
of Rilonacept (interleukin-1 trap) in patients with cryopyrin-associated
periodic syndromes.
Arthritis Rheum 2008;58:2443-52.
[PubMed: 18668535]
74. Muckle TJ, Wells M. Urticaria, deafness, and amyloidosis:
a new heredo-familial syndrome.
Q J Med. 1962;31:235-248.
[PubMed: 14476827]
75. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum
of clinical features in Muckle-Wells Syndrome and response to anakinra.
Arthritis
Rheum. 2004;50:607-612.
[PubMed: 14872505]
76. Hawkins PN, Lachmann HJ, E, McDermott MF. Interleukin-1-receptor
antagonist in the Muckle-Wells syndrome.
N Engl J Med.
2003;348:2583-2584.
[PubMed: 12815153]
77. Prieur AM, Griscelli C. Arthropathy with rash, chronic meningitis,
eye lesions, and mental retardation.
J Pediatr. 1981;99:79-83.
[PubMed: 7252669]
78. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1
mutations, cytokine activation, and evidence for genetic heterogeneity
in patients with neonatal-onset multisystem inflammatory disease
(NOMID): a new member of the expanding family of pyrin-associated
autoinflammatory diseases.
Arthritis Rheum. 2002;46:3340-3348.
[PubMed: 12483741]
79. Hashkes PJ, Lovell DL. Recognition of infantile-onset multisystem
inflammatory disease as a unique entity.
J Pediatr.
1997;130:513-515.
[PubMed: 9108844]
80. Federico G, Rigante D, Pugliese AL, Ranno O, Catania S,
Stabile A. Etanercept induces improvement of arthropathy in chronic
infantile neurological cutaneous articular (CINCA) syndrome.
Scand J
Rheumatol. 2003;32:312-314.
[PubMed: 14690147]
81. Frenkel J, Wulffratt NM, Kuis W. Anakinra in mutation-negative
NOMID/CINCA syndrome: comment on the articles by Hawkins
et al and Hoffman and Patel.
Arthritis Rheum. 2004; 50:3738-3739.
[PubMed: 15529342]
82. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade
by anakinra improves clinical symptoms in patients with neonatal-onset
multisystem inflammatory disease.
Arthritis Rheum.
2005;52:1283-1286.
[PubMed: 15818707]
83. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-Onset
Multisystem Inflammatory Disease responsive to interleukin-1 inhibition.
N
Engl J Med. 2006;355:581-592.
[PubMed: 16899778]
84. Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT.
A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma
gangrenosum and acne: PAPA syndrome.
Mayo Clin Proc.
1997;72:611-615.
[PubMed: 9212761]
85. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1
disrupt binding to PTP PEST and are responsible for PAPA syndrome,
an autoinflammatory disorder
. Hum Mol Genet. 2002;11:961-969.
[PubMed: 11971877]
86. Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the
PSTPIP1/CD2BP1 protein, defining familial Mediterranean
fever and PAPA as disorders in the same pathway. Proc Natl
Acad
Sci USA. 2003;100:13501-13506.
[PubMed: 14595024]
87. Cortis E, De Benedetti F, Insalaco A, et al. Abnormal production
of tumor necrosis factor (TNF)—alpha and clinical efficacy
of the TNF inhibitor etanercept in a patient with PAPA syndrome.
J
Pediatr. 2004;145:851-855.
[PubMed: 15580218]
88. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. Anakinra
for flares of pyogenic arthritis in PAPA syndrome.
Rheumatology
(Oxford). 2005;44:406-408.
[PubMed: 15637033]
89. Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of
periodic fever, pharyngitis, and aphthous stomatitis.
J
Pediatr. 1987;110:43-46.
[PubMed: 3794885]
90. Thomas KT, Feder HM Jr, Lawton AR, Edwards KM. Periodic
fever syndrome in children.
J Pediatr. 1999;135:15-21.
[PubMed: 10393598]
91. Padeh S, Brezniak N, Zemer D, et al. Periodic fever, aphthous
stomatitis, pharyngitis, and adenopathy syndrome: Clinical characteristics
and outcome.
J Pediatr.1999;135:98-101.
[PubMed: 10393612]
92. Tasher D, Somekh E, Dalal I. PFAPA syndrome—new
clinical aspects revealed
. Arch Dis Child. 2006;91:981-984.
[PubMed: 16595648]
93. Feder HM Jr. Cimetidine treatment for periodic fever associated
with aphthous stomatitis, pharyngitis and cervical adenitis.
Pediatr
Infect Dis J. 1992;11:318-321.
[PubMed: 1565557]
94. Abramson JS, Givner LB, Thompson JN. Possible role of tonsillectomy
and adenoidectomy in children with recurrent fever and tonsillopharyngitis. Pediatr
Infect Dis J. 1989;8:199-220.
95. Renko M, Sal E, Putto-Laurila A, et al. A randomized, controlled
trial of tonsillectomy in periodic fever, aphthous stomatitis, pharyngitis and
adenitis syndrome.
J Pediatr. 2007;151:289-292.
[PubMed: 17719940]
96. Giedion A, Holthusen W, Masel LF, Vischer D. Subacute and
chronic “symmetrical” osteomyelitis.
Ann
Radiol. 1972;15:329-342.
[PubMed: 4403064]
97. Ferguson PL, El-Shanti EI. Autoinflammatory bone disorders.
Curr
Opin Rheumatol. 2007;19: 492-498.
[PubMed: 17762617]
98. Majeed HA, Kalaawi M, Mohanty D, et al. Congenital dyserythropoietic
anemia and chronic recurrent multifocal osteomyelitis in three related
children and the association with Sweet syndrome in two siblings.
J
Pediatr. 1989;115: 730-734.
[PubMed: 2809904]
99. Ferguson PJ, Chen S, Tayeh MK et al. Homozygous mutations
in LPIN2 are responsible for the syndrome of chronic recurrent multifocal
osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome).
J Med
Genet. 2005;42:551-557.
[PubMed: 15994876]
100. Ueki Y, Tiziani V, Santanna C, et al. Mutations in the
gene encoding c-Abl-binding protein SH3BP2 cause cherubism.
Nat
Genet. 2001; 28:125-126.
[PubMed: 11381256]
101. Ferguson PL, Chen S, Tayeh MK, et al. A missense mutation
in pstpip2 is associated with the murine autoinflammatory disorder
chronic multifocal osteomyelitis.
Bone. 2006;38:41-47.
[PubMed: 16122996]
102. Laxer RM, Shore AD, Manson D, et al. Chronic recurrent
multifocal osteomyelitis and psoriasis – a report of a
new association and review of related disorders.
Semin Arthritis Rheum.
1988;17:260-270.
[PubMed: 2976529]
103. Job-Deslandre C, Krebs S, Kahan A. Chronic recurrent multifocal
osteomyelitis: five-year outcomes in 14 pediatric cases
.
Joint Bone Spine. 2001;68:245-251.
[PubMed: 11394625]
104. Duffy CM, Lam PY, Ditchfield M, et al. Chronic recurrent
multifocal osteomyelitis: review of orthopaedic complications at
maturity.
J Pediatr Orthop. 2002;22:501-505.
[PubMed: 12131448]
105. Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E,
Grosshans E. The Schnitzler syndrome. Four new cases and review
of the literature.
Medicine (Baltimore). 2001;80:37-44.
[PubMed: 11204501]
106. de Koning HD, Bodar EJ, van der Meer JW, Simon A for the
Schnitzler Syndrome Study Group. Schnitzler syndrome: beyond the
case reports: review and follow-up of 94 patients with an emphasis
on prognosis and treatment. Semin Arthritis Rheum.
2007;37:137-148.
107. Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luma
JL. Successful treatment of refractory Schnitzler syndrome with
anakinra: comment on the article by Hawkins et al.
Arthritis
Rheum. 2005;52:2226-2227.
[PubMed: 15986356]
108. Granel B, Serratrice J, Dode C, Grateau G, Disdier P, Weiller
PJ. Overlap syndrome between FMF and TRAPS in a patient carrying MEFV
and TNFRSF1A mutations. Clin Exp Rheumatol. 2007;25(4
Suppl 45):S93-S95.
109. Stojanov S, Lohse P, Lohse P, et al. Molecular analysis
of the MVK and TNFRSF1A genes in patients with a clinical presentation
typical of the hyperimmunoglobulinemia D with periodic fever syndrome:
a low-penetrance TNFRSF1A variant in a heterozygous MVK carrier
possibly influences the phenotype of hyperimmunoglobulinemia D with
periodic fever syndrome or vice versa.
Arthritis Rheum.
2004;50:1951-1958.
[PubMed: 15188372]
110. Touitou I, Magne X, Molinari N, et al. MEFV mutations in
Behçet disease.
Hum Mutat. 2000;16:271-272.
[PubMed: 10980540]
111. Sari S, Egritas O, Dalgic B. The familial Mediterranean
fever (MEFV) gene may be a modifier factor of inflammatory bowel
disease in infancy. Eur J Pediatr. 2007 [Epub
ahead of print].
112. Rozenbaum M, Rosner Y. Severe outcome of juvenile idiopathic
arthritis (JIA) associated with familial Mediterranean fever (FMF). Clin Exp
Rheumatol. 2004;22(Suppl 34):S75-S78.
113. Canete JD, Arostegui JI, Queiro R, et al. An unexpectedly
high frequency of MEFV mutations in patients with anticitrullinated
protein antibody-negative palindromic rheumatism.
Arthritis
Rheum. 2007;56:2784-2788.
[PubMed: 17665427]
114. Atagunduz MP, Tuglular S, Kantarci G, Akoglu E, Direskeneli
H. Association of FMF-related (MEFV) point mutations with secondary
and FMF amyloidosis. Nephron Clin Pract. 2004;
96:c131-c135.
115. Peru H, Altun B, Dogan M, Kara F, Elmaci AM, Oran B. The
evaluation of carotid intima-media thickness in children with familial
Mediterranean fever. Clin Rheumatol. 2007 [Epub ahead
of print].
116. Miller LC, Sisson BA, Tucker LB, Schaller JG. Prolonged
fevers of unknown origin in children: patterns of presentation an
outcome.
J Pediatr. 1996;129:419-423.
[PubMed: 8804332]
117. John C, Gilsdorf J. Recurrent fever in children.
Pediatr
Infect Dis J. 2002;21:1071-1077.
[PubMed: 12442033]
118. Long SS. Distinguishing among prolonged, recurrent, and
periodic fever syndromes: approach of a pediatric infectious diseases
subspecialist.
Pediatr Clin North Am. 2005;52:811-835.
[PubMed: 15925664]
119. Chitkara P, Jayamuni S, Athreya BH, et al. Undifferentiated
periodic fever syndrome—a long term follow up study [late
abstract]. American College of Rheumatology, 2006.
120. Grateau G. Clinical and genetic aspects of the hereditary
periodic fever syndromes.
Rheumatology. 2004;43:410-415.
[PubMed: 14983109]
121. Federici L, Rittore-Domingo C, Kone-Paut I, et al. A decision
tree for genetic diagnosis of hereditary periodic fevers in unselected patients. Ann
Rheum Dis. 2006;65:142741532.
122. McDermott MF. Genetic clues to understanding periodic fevers,
and possible therapies.
Trends Mol Med. 2002;8:550-554.
[PubMed: 12470987]
123. Samuels J, Ozen S. Familial Mediterranean fever and other
autoinflammatory syndromes: evaluation of the patient with recurrent
fever.
Curr Opin Rheum. 2006;18:108-117.
[PubMed: 16344627]
124. Simon A, van der Meer JW, Vesely R, et al. Approach to
genetic analysis in the diagnosis of hereditary autoinflammatory
syndromes.
Rheumatology (Oxford). 2006;45:269-273.
[PubMed: 16234278]